Dr Reddy's Laboratories is presenting six abstracts representing its discovery research findings at the 63rd scientific sessions of the American Diabetes Association being held from June 13 to 17 at New Orleans, US. This is the third successive year that Dr Reddy's is presenting its research findings at the ADA.
The American Diabetes Association is a leading non-profit health organisation that provides diabetes research, information and advocacy. More than 8,000 participants, including physicians, scientists and other healthcare professionals involved in diabetes research and care, were expected to attend the scientific sessions.
A statement issued by Dr Reddy's said that the abstracts being presented would focus on the progress of Dr Reddy's discovery programme. The presentation would include a demonstration of pre-clinical efficacy and safety of the company's pipeline compounds under development for the treatment of type-II diabetes, discovery of potential new diagnostic markers for the onset of type-II diabetes and mechanisms of accelerated cardio-vascular disease in diabetes.
The annual ADA meetings are the premier platform for the presentation of diabetes-related research. The abstracts are peer reviewed before being accepted for presentation. The DRL statement also announced that the company would hold its Scientific Advisory Board meeting at New Orleans on Saturday, June 14. The Board, consisting of international scientific opinion leaders, would review the progress in the company's discovery research programme in the areas of diabetes, cardio-vascular disease and inflammation.
This will be followed by a clinical consortium meeting in Atlanta on June 18. The consortium will consist of a panel of international experts who will review the progress and strategy for the clinical development of the company's anti-cancer molecules.